Skip to main content
  • Auricula Biosciences
  • Investment: 2022
  • Status: Active

Auricula Biosciences is a project-focused company currently developing a first-in-class targeted therapeutic for a broad set of K-Ras mutant malignancies to clinical proof-of-concept. Ras mutation is the most frequent oncogenic alteration in human cancers and confers a poor prognosis as current targeted therapies are effective only in a minority of patients and hampered by the development of drug resistance. Auricula’s therapeutic candidate has been designed to bypass such resistance.

Involved Team

Dr. Luc Marengère
Managing Partner

Dr. Cynthia Cardinal (CEO)